Nektar Therapeutics (NKTR) Reports Q4 Loss of $0.21
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $59.38 +0.29%
EPS Growth %: +96.4%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: +96.4%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.21), versus ($0.28) reported last year. Revenue for the quarter came in at $95.5 million, versus $37.5 million reported last year.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Stitch Fix (SFIX) Tops Q3 EPS by 4c, Offers Guidance
- Oracle (ORCL) Tops Q4 EPS by 16c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
